Pegcetacoplan (APL-2)
APL2-ALS-206
Phase 2 small_molecule terminated
Quick answer
Pegcetacoplan (APL-2) for Amyotrophic Lateral Sclerosis is a Phase 2 program (small_molecule) at Apellis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Apellis Pharmaceuticals
- Indication
- Amyotrophic Lateral Sclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated